
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K/A

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported)
July 28, 2016**

AKEBIA THERAPEUTICS, INC.

(Exact name of registrant as specified in charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36352
(Commission
File Number)

20-8756903
(I.R.S. Employer
Identification No.)

245 First Street, Suite 1100, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices, including Zip Code)

(617) 871-2098
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This amended Current Report on Form 8-K/A (this “Report”) amends certain information included in a Current Report on Form 8-K filed by Akebia Therapeutics, Inc. (the “Company”) on July 28, 2016 (the “Original Filing”) regarding the election of Scott A. Canute by the Board of Directors of the Company (the “Board”), effective as of July 29, 2016. At the time of the Original Filing, the Board had not made a determination regarding any committee assignment for Mr. Canute. At a regular meeting of the Board held on December 8, 2016, the Board appointed Mr. Canute to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, effective as of January 1, 2017.

Other than the preceding disclosure, no other disclosure reported in the Original Filing is amended pursuant to this Report.

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 14, 2016

AKEBIA THERAPEUTICS, INC.

By: /s/ John P. Butler

John P. Butler
President and Chief Executive Officer